Peptide Therapy in Ophthalmology: Applications, Pipeline, and Market Outlook

A New Era for Eye Disease Treatment

Eye diseases like age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy affect hundreds of millions of people worldwide. Current treatments help many patients, but they come with real limitations.

Peptide therapy is opening new possibilities in ophthalmology. Peptides can target specific biological pathways in the eye with precision that older drugs cannot match.

"The future of retinal therapeutics lies in peptide engineering that combines target specificity with sustained ocular bioavailability, reducing the injection burden that drives poor patient compliance." , Peter K. Kaiser, Professor of Ophthalmology, Cole Eye Institute, Cleveland Clinic, Review of Ophthalmology (2024)

Why the Eye Is a Unique Drug Delivery Environment

The eye is a specialized organ with its own unique barriers and biology. Getting any drug to the right part of the eye is a significant challenge.

The blood-retinal barrier protects the inner eye from many circulating compounds. This means drugs designed for retinal diseases must either be injected directly into the eye or formulated to cross this barrier efficiently.

Expert Quote: "Peptides are surprisingly well-suited to ocular drug delivery. Their small size relative to antibodies, combined with target specificity, makes them attractive for both intravitreal injection and surface delivery." - Ophthalmology Drug Development Director, Specialty Pharma Company

The intravitreal injection route, which involves injecting directly into the vitreous humor of the eye, allows for high local drug concentrations while minimizing systemic exposure. Many leading peptide eye drugs use this route.

Key Ophthalmic Conditions Being Targeted

Peptide therapy research is active across several major eye diseases. Each condition presents different biological targets and delivery challenges.

Condition	Estimated Global Prevalence	Key Biological Target
Age-related macular degeneration (AMD)	196 million	VEGF, complement system
Diabetic retinopathy	100 million	VEGF, inflammation, neurodegeneration
Glaucoma	80 million	IOP reduction, neuroprotection
Dry eye disease	344 million	Inflammation, tear film
Corneal injury and healing	Variable	Growth factor pathways
Retinitis pigmentosa	1.5 million	Photoreceptor neuroprotection

AMD and diabetic retinopathy are the largest market opportunities because of their high prevalence and the high treatment costs of existing therapies.

Peptides Targeting VEGF and Angiogenesis

Vascular endothelial growth factor (VEGF) drives the abnormal blood vessel growth that causes vision loss in wet AMD and diabetic retinopathy. Anti-VEGF drugs are already the standard of care, but most are large antibody molecules that require regular injections.

Peptides offer a compelling alternative. Anti-VEGF peptides are smaller, potentially cheaper to manufacture, and may offer longer duration of action in the eye.

Several companies are developing VEGF-binding peptides specifically for ocular use. The goal is to match or exceed the efficacy of antibody-based anti-VEGF drugs while reducing injection frequency.

Neuroprotective Peptides for Glaucoma and Retinal Degeneration

Glaucoma damages the optic nerve over time, and current treatments focus almost entirely on lowering intraocular pressure. But pressure control alone does not stop all neurodegeneration.

Neuroprotective peptides that directly protect retinal ganglion cells from damage are being actively studied. These peptides target survival signaling pathways and reduce neuroinflammation.

Peptide analogs of ciliary neurotrophic factor (CNTF), brain-derived neurotrophic factor (BDNF), and pigment epithelium-derived factor (PEDF) have all shown activity in protecting retinal neurons in animal models.

Retinal ganglion cells, once lost to glaucoma damage, do not regenerate in humans. This makes neuroprotection a critical unmet need, and peptide-based strategies are among the most promising approaches being studied.

Dry Eye Disease: A Large and Growing Market

Dry eye disease affects hundreds of millions of people and is significantly underserved by current treatments. Most approved drugs treat inflammation at the eye surface, but they do not address all the underlying causes.

Peptides targeting the lacrimal gland, mucin production, and ocular surface inflammation are in development. These address dry eye from multiple biological angles simultaneously.

The dry eye market exceeded $5 billion globally in 2024 and is growing rapidly. Peptide drugs with better tolerability and longer-lasting effects than existing options could capture significant market share.

Corneal Healing and Regenerative Peptides

The cornea heals poorly after injury or surgery in some patients. Peptides derived from growth factors like EGF, KGF, and substance P have been studied for their ability to accelerate corneal epithelial healing.

Topical peptide formulations for corneal healing are particularly attractive because they can be applied as eye drops, avoiding the need for injections. Stability in the aqueous eye drop environment is a key formulation challenge.

Several peptide-based eye drops for corneal regeneration and wound healing are available in some markets and in development in others.

Market Size and Growth Projections

The global ophthalmic drug market was valued at approximately $30 billion in 2024. The peptide segment within this market is small today but growing rapidly.

Market Segment	2024 Value	Projected 2030 Value	Growth Driver
Anti-VEGF drugs (AMD, DR)	$12 billion	$16 billion	Aging population
Glaucoma treatments	$6 billion	$8 billion	Increased diagnosis rates
Dry eye therapies	$5 billion	$9 billion	Screen time, aging
Corneal/ocular surface	$2 billion	$3.5 billion	Surgical volume
Neuroprotection (emerging)	Less than $1 billion	$2 to 3 billion	Unmet need

Peptide-based drugs are positioned to take share in most of these segments as clinical data matures.

Delivery Technologies for Ophthalmic Peptides

Getting peptides to the right place in the eye is a major technical challenge. Several delivery platforms are being developed to address this problem.

Delivery System	Target Region	Key Advantage
Intravitreal injection	Retina, vitreous	Direct access to posterior segment
Topical eye drops	Cornea, conjunctiva	Non-invasive, easy to use
Sustained-release implants	Vitreous, subretinal	Reduces injection frequency
Hydrogel formulations	Anterior and posterior	Extended residence time
Nanoparticle carriers	Multiple regions	Can cross ocular barriers
Contact lens delivery	Corneal surface	Continuous, controlled release

Sustained-release implants are of particular interest for retinal diseases. Reducing injection frequency from monthly to every six months or longer would greatly improve the patient experience.

According to data from the National Institutes of Health, ophthalmic drug delivery research is one of the most active areas in pharmaceutical science, with hundreds of peer-reviewed studies published each year on new approaches to ocular drug targeting.

Regulatory Considerations for Ophthalmic Peptides

Ophthalmic drugs face specific regulatory requirements that differ from systemic drugs. The FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) both have jurisdiction over different types of ophthalmic products.

Sterility is an absolute requirement for any drug that touches the eye, especially injectables. Manufacturing peptide-based ophthalmic drugs under strict aseptic conditions adds cost and complexity.

Ocular safety studies including corneal tolerability testing, lens toxicity assessment, and electroretinography (ERG) testing are typically required for regulatory submissions.

Learn about how peptide research teams are being built to support ophthalmology programs

Key Companies and Pipeline Activity

The ophthalmic peptide pipeline includes both large pharmaceutical companies and focused biotechs. Novartis, Roche/Genentech, and Regeneron are active in anti-VEGF peptides. Multiple smaller companies are pursuing neuroprotection and dry eye applications.

Clinical trial activity in ophthalmic peptides has increased significantly over the past five years. Several Phase II and Phase III trials are ongoing, suggesting that approved products could reach market within the next three to five years.

See how peptide therapy market trends are developing in other therapeutic areas

FAQ: Peptide Therapy in Ophthalmology

What eye diseases can be treated with peptide therapies? Current research targets wet AMD, diabetic retinopathy, glaucoma, dry eye disease, corneal injuries, and retinal degenerative diseases like retinitis pigmentosa.

Are any peptide-based eye drugs already approved? Several peptide-containing ophthalmic products are approved in various markets for corneal healing and dry eye. Anti-VEGF peptides for AMD are in advanced clinical development.

Why are injections necessary for many eye diseases? Many serious eye diseases affect the retina, which is inside the eye behind multiple barriers. Injecting directly into the vitreous humor is the most reliable way to deliver drugs to the retina.

How does peptide therapy compare to antibody-based eye drugs? Peptides are smaller than antibodies, which may allow them to penetrate eye tissues more effectively. They can also be less expensive to manufacture and may offer different duration of action profiles.

What is the market size for ophthalmic peptide drugs? The broader ophthalmic drug market is about $30 billion. Peptide-specific revenues are currently a small fraction but are growing rapidly as clinical programs mature.

How do sustained-release implants work for ophthalmic peptide delivery? A small device or biodegradable implant is placed inside the eye and slowly releases the peptide drug over weeks to months. This reduces how often patients need injections.

What are the main regulatory requirements for new ophthalmic peptide drugs? Key requirements include sterility and aseptic manufacturing, ocular safety studies (including corneal and lens toxicity), clinical efficacy data from randomized controlled trials, and stability testing under relevant storage conditions.